

Non-Malignant Hematology Pipeline



Phase I

- **Crovalimab**
(C5 complement inhibitor)
Sickle Cell Disease

Phase II

- **Crovalimab**
(C5 complement inhibitor)
Sickle Cell Disease
- **SPK-8011**
Hemophilia A
- **SPK-8016**
Hemophilia A with inhibitors
to factor VIII

Phase III

- **Crovalimab**
(C5 complement inhibitor)
Paroxysmal Nocturnal Hemoglobinuria,
Atypical Hemolytic Uremic Syndrome
- **Emicizumab**
Moderate to mild hemophilia A,
Hemophilia A in Infants (0-12 months)

Disease State



These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration or the European Medicines Agency. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

The Oncology Pipeline information is consistent with Roche's Q3 Year Results 2021 presentation (as of October 22, 2021). Available at <https://www.roche.com/dam/jcr:d7745cfb-1133-447e-9a5b-88b849495574/en/irp211020-a.pdf> and <https://www.clinicaltrials.gov/ct2/show/NCT05075824>, <https://clinicaltrials.gov/ct2/show/NCT04431726?term=haven+7&draw=2&rank=1>.

SCD=sickle cell disease; PNH=paroxysmal nocturnal hemoglobinuria; aHUS=atypical hemolytic uremic syndrome. HemA=hemophilia A